BioNTech, which specialises in the development of therapies to treat cancer and infectious diseases, will receive upfront, equity and near-term research payments of $120 million under the terms of the deal, with up to $305 million to follow based on the achievement of various developmental, regulatory and commercialisation milestones.
Original Article: Pfizer partners up with BioNTech for $425m to pursue mRNA flu vaccines